Cargando…

MK2 is a therapeutic target for high-risk multiple myeloma

Detalles Bibliográficos
Autores principales:	Gu, Chunyan, Cheng, Haibo, Yang, Hongbao, Bian, Yong, Wang, Yaohui, Zhang, Yifen, Pisano, Michael, Hu, Gang, Yang, Ye
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Fondazione Ferrata Storti 2018
Materias:	Letters to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8168486/ https://www.ncbi.nlm.nih.gov/pubmed/29567777 http://dx.doi.org/10.3324/haematol.2017.182121

Ejemplares similares

Targeting MK2 Is a Novel Approach to Interfere in Multiple Myeloma
por: Guo, Mengjie, et al.
Publicado: (2019)

WDR26 and MTF2 are therapeutic targets in multiple myeloma
por: Sun, Fumou, et al.
Publicado: (2021)

CAR-T therapy alters synthesis of platelet-activating factor in multiple myeloma patients
por: Ke, Mengying, et al.
Publicado: (2021)

MTDH is an oncogene in multiple myeloma, which is suppressed by Bortezomib treatment
por: Gu, Chunyan, et al.
Publicado: (2015)

Evolving therapeutic role of bisphosphonates in multiple myeloma
por: Ural, A U, et al.
Publicado: (2005)

Therapeutic targeting of PFKFB3 and PFKFB4 in multiple myeloma cells under hypoxic conditions
por: Okabe, Seiichi, et al.
Publicado: (2022)

Heat shock factor 1 is a potent therapeutic target for enhancing the efficacy of treatments for multiple myeloma with adverse prognosis
por: Bustany, Sophie, et al.
Publicado: (2015)

HNRNPA2B1 promotes multiple myeloma progression by increasing AKT3 expression via m6A-dependent stabilization of ILF3 mRNA
por: Jiang, Fengjie, et al.
Publicado: (2021)

Multiple Myeloma and Alkaline Phosphatase
por: Yavaşoğlu, İrfan, et al.
Publicado: (2015)

Carbamazepine and Multiple Myeloma: Possible Interaction
por: Günaldı, Meral, et al.
Publicado: (2013)

Daratumumab in dialysis-dependent multiple myeloma
por: Jeyaraman, Preethi, et al.
Publicado: (2020)

Seronegative rheumatoid arthritis as the first manifestation of multiple myeloma-associated amyloid arthropathy
por: Wang, Gang, et al.
Publicado: (2023)

Pomalidomide-based regimens bridging CAR-T therapy in multiple myeloma with central nervous system involvement
por: Zhang, Qiqi, et al.
Publicado: (2022)

Multiple myeloma presenting with focal segmental glomerulosclerosis
por: Valizadeh, Nasim, et al.
Publicado: (2013)

Oligosecretory multiple myeloma: a case report
por: Khurana, Ujjawal, et al.
Publicado: (2016)

The Coexistence of Chronic Lymphocytic Leukemia and Multiple Myeloma
por: Hangül, Ceren, et al.
Publicado: (2019)

An Unconventional Presentation of Multiple Myeloma: Bazex Syndrome
por: Kandemir Alibakan, Özlem, et al.
Publicado: (2020)

Renal cell carcinoma concomitant with multiple myeloma
por: Narwal, Anubhav, et al.
Publicado: (2022)

Talquetamab: A promising immunotherapy for multiple myeloma
por: Tariq, Amna, et al.
Publicado: (2023)

Multiple Myeloma: An Unexpected Cause of Dysphagia After Cervical Spine Surgery
por: Chen, Chang Jun, et al.
Publicado: (2023)

Targeting B-cell maturation antigen increases sensitivity of multiple myeloma cells to MCL-1 inhibition
por: Cuenca, Marta, et al.
Publicado: (2021)

Safe and successful CAR T-cell therapy targeting BCMA in a multiple myeloma patient requiring hemodialysis
por: Wäsch, Ralph, et al.
Publicado: (2023)

Nonsecretory multiple myeloma, how to make a diagnosis?
por: Wiwanitkit, Viroj
Publicado: (2010)

Austrian Syndrome and Multiple Myeloma: A Fatal Combination
por: Baig, Abdur, et al.
Publicado: (2012)

Empyema Necessitans: An Unexpected Infectious Presentation of Multiple Myeloma
por: Kapila, Aaysha, et al.
Publicado: (2017)

BTK suppresses myeloma cellular senescence through activating AKT/P27/Rb signaling
por: Gu, Chunyan, et al.
Publicado: (2017)

Trends of survival in patients with multiple myeloma in Japan: a multicenter retrospective collaborative study of the Japanese Society of Myeloma
por: Ozaki, S, et al.
Publicado: (2015)

Chimeric antigen receptors containing the OX40 signalling domain enhance the persistence of T cells even under repeated stimulation with multiple myeloma target cells
por: Tan, Jingwen, et al.
Publicado: (2022)

Single‐cell RNA sequencing infers the role of malignant cells in drug‐resistant multiple myeloma
por: Wang, He‐nan, et al.
Publicado: (2021)

Under-representation of ethnic minorities in early phase clinical trials for multiple myeloma
por: Asher, Samir, et al.
Publicado: (2022)

Idiopathic thrombocytopenic purpura treatment in a relapsed/refractory multiple myeloma patient after chimeric antigen receptor T cell therapy
por: Qiu, Lei, et al.
Publicado: (2020)

Multiple myeloma and fever of unknown origin: a need for therapy
por: Mumoli, N, et al.
Publicado: (2005)

Prevalence, incidence and survival of smoldering multiple myeloma in the United States
por: Ravindran, A, et al.
Publicado: (2016)

A case of synchronous multiple myeloma and chronic myeloid leukemia
por: Lee, Ji-Young, et al.
Publicado: (2017)

Identifying the link between multiple myeloma and neurofibromatosis type I
por: Rago, Angela, et al.
Publicado: (2020)

The Outcome of Six Patients with COVID-19 Infection and Multiple Myeloma
por: Elsabah, Hesham, et al.
Publicado: (2020)

IgA nephropathy in IgG kappa multiple myeloma
por: Couto, Maria Eduarda, et al.
Publicado: (2021)

Cutaneous secondary localization of multiple myeloma at Heparin injection sites
por: Borg, Emma, et al.
Publicado: (2023)

Elrexfio™ (elranatamab-bcmm): The game-changer in treatment of multiple myeloma
por: Rais, Taruba, et al.
Publicado: (2023)

“A beacon of hope for relapsed multiple myeloma patients: TALVEY™”
por: Khaliq, Nawal, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_g5kfjerfvkk8058c8ufi9qsov2